Articles
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
The catalyst for this renewed interest is the USPTO Appeals Review Panel's Ex parte Chamberlain decision and the Federal Circuit decision on appeal.
Pharmaceutical Executive
By Scott A. Warren
Share on:
Scott A. Warren authored the Pharmaceutical Executive article, "A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims." View the full article.
